Method and composition for treating cystic fibrosis
US5981592A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 9, 1998 |
| Grant date | Nov 9, 1999 |
| Priority date | — |
| Expiry date | Apr 9, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/407
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition for use in preventing colorectal cancer and other neoplastic diseases, such as breast cancer, includes an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof in an amount effective to elicit a chemoprotective effect. The composition is substantially free of the S-enantiomer of the R-NSAID. Therapeutic use of the composition is accompanied by reduced adverse side effects. A method of treating cystic fibrosis likewise includes the step of administering to a patient in need of such treatment a composition having an effective cystic fibrosis therapeutic amount of an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof, the composition being substantially free of the S-enantiomer of the selected R-NSAID.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.